At 3.8% CAGR, Asia Pacific Feed Anticoccidials Market is Projected to be Worth US$ 650.92 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific feed anticoccidials market was valued at US$ 482.72 million in 2023 and is expected to reach US$ 650.92 million by 2031, registering a CAGR of 3.8% from 2023 to 2031. Rise in prevalence of coccidiosis and increase in livestock production are among the critical factors attributed to the Asia Pacific feed anticoccidials market expansion.

Coccidiosis is a type of gastrointestinal infection in animals caused by coccidian protozoa. When an animal comes in contact with infected feces or tissue, the disease is transmitted. Diarrhea is the primary symptom of coccidiosis. The majority of poultry coccidiosis is highly host-specific and is caused by the genus Eimeria.

Coccidiosis directly infects animals and reduces their performance; it results in large economic losses. Owing to its direct impact on flock appearance and intestinal health, it is a major global concern in the poultry industry. The EW Nutrition Technical Team reports that coccidial illness costs the poultry sector more than US$ 14 billion a year and is a serious intestinal problem. Owing to damage to the intestinal cells, the disease results in decreased body weights, increased feed conversion rates, abnormalities in skin color, irregular flock sizes, and ultimately, death. According to DSM, across the world, yearly losses were estimated at more than US$ 3 billion due to coccidiosis in chickens and other avian species. Thus, coccidiosis prevention is becoming essential for producers, veterinary associations, and regulatory authorities of various countries.

According to the World Health Organization (WHO), the usage of antibiotics such as anticoccidial in animal feed as an additive can treat infections. There is a surge in the use of anticoccidials in feed by animal feed manufacturers to fight against infection in animals, overcome losses, and improve farm profitability. Thus, the rising prevalence of coccidiosis fuels the feed anticoccidial market growth.

On the contrary, stringent regulation on use of antibiotics in animal feed hamper the growth of Asia Pacific feed anticoccidials market.

Based on type, the Asia Pacific feed anticoccidials market is segmented into ionophore, chemical anticoccidials, and chemical-ionophores. The ionophore segment held 42.5% market share in 2023, amassing US$ 205.22 million. It is projected to garner US$ 267.11 million by 2031 to register 3.3% CAGR during 2023-2031.

In terms of form, the Asia Pacific feed anticoccidials market is bifurcated into dry and liquid. The dry segment held 93.7% share of Asia Pacific feed anticoccidials market in 2023, amassing US$ 452.45 million. It is projected to garner US$ 608.46 million by 2031 to expand at 3.8% CAGR during 2023-2031.

Based on livestock, the Asia Pacific feed anticoccidials market is segmented into poultry, ruminants, swine, and others. The poultry segment held 77.1% market share in 2023, amassing US$ 372.26 million. It is projected to garner US$ 496.93 million by 2031 to register 3.7% CAGR during 2023-2031.

Based on country, the Asia Pacific feed anticoccidials market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 51.8% share of Asia Pacific feed anticoccidials market in 2023. It was assessed at US$ 249.95 million in 2023 and is likely to hit US$ 330.73 million by 2031, exhibiting a CAGR of 3.6% during 2023-2031.

Key players operating in the Asia Pacific feed anticoccidials market are Phibro Animal Health Corp, Zoetis Inc, Kemin Industries Inc, Elanco Animal Health Inc, Innovista Feeding Solutions Pvt Ltd, Huvepharma EOOD, Impextraco NV, Virbac SA., International Animal Health Products Pty Ltd, and Zamira Australia Ltd, among others.

• In March 2021, Baur & Co Ltd joined Elanco Animal Health in launching two new veterinary products in Sri Lanka, introducing two new products to the livestock sector. Maxiban 25 Kg, an Anticoccidial feed additive for Coccidiosis, and Pulmotil AC, a veterinary drug for Mycoplasma Gallicepticum.
• In April 2024, Zoetis and Phibro Animal Health acquired Zoetis' medicated feed additive product portfolio, water soluble products, and related assets for $350 million. The acquisition, which generated $400 million in revenue in 2023, includes over 37 product lines and six manufacturing sites. The transaction is expected to be completed in the second half of 2024. Over 300 Zoetis colleagues are expected to transition to Phibro Animal Health.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com